Detalles del proyecto
| Estado | Finalizado |
|---|---|
| Fecha de inicio/Fecha fin | 10/19/21 → 8/24/23 |
Financiación
- AstraZeneca Pharmaceuticals LP (domestic): 21.830,00 US$
A Phase 1/2a, Open-Label, Multicentre Study To Evaluate The Safety, Pharmacokinetics, And Preliminary Efficacy Of Subcutaneous Durvalumab In Patients With Non-Small Cell And Small Cell Lung Cancer -- SCope-D1
- Arnold, Susanne M (PI)